ClinicalTrials.gg
CompletedNCT02284893Updated Jun 1, 2018Results posted

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

A Phase 3 interventional study of Saxagliptin and Dapagliflozin in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 79 sites in 6 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2018-06-01.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.

Enrollment
20th of 74
461 · median 138
Started
2014
with 9 others
Phase 3
27 of 74
none open now
Registered
56th of 74
by date
Lead sponsor
48 of 74
AstraZeneca

Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 20th largest by enrollment, is one of 10 that started in 2014, is one of 27 in phase 3, and was the 56th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Patients with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control, defined as a central laboratory glycosylated () ≥8.0% and ≤ 10.5 % obtained at the screening visit
  • Subjects should have been taking the same daily dose of metformin ≥ 1500 mg for at least 8 weeks prior to the enrollment visit and with no intake of other antihyperglycemic therapy for more than 14 days (consecutive or not) during 12 weeks prior to screening
  • > 20.0 kg/m2 at the enrollment visit
  • Males and Females, age ≥18 years old at time of screening visit
  • Women of (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug
  • Women must not be breastfeeding

Exclusion criteria

Exclusion Criteria:

  • Clinically diagnosed with Type I diabetes, known diagnosis of Maturity Onset Diabetes of Young (MODY), secondary diabetes mellitus or diabetes insipidus
  • History of diabetic ketoacidosis
  • Any of the following cardiovascular (CV)/Vascular Diseases within 3 months of the enrollment visit

    • Myocardial infarction
    • Cardiac surgery or revascularization (coronary artery bypass surgery Coronary Artery Bypass Graft [(CABG)]/percutaneous transluminal coronary angioplasty percutaneous transluminal coronary angioplasty [(PTCA)])
    • Unstable angina
    • Unstable congestive heart failure (CHF)
    • (TIA) or significant cerebrovascular disease
    • Unstable or previously undiagnosed arrhythmia
    • Congestive heart failure, defined as (NYHA) Class III and IV, unstable or acute congestive heart failure and/or known of ≤ 40%
  • Renal Disease
  • Hepatic Diseases
  • Hematological and Oncological Disease/Conditions
  • ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women
  • Abnormal Free T4
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
461 participants (actual)

Study arms

  • Experimental
    A1:Saxagliptin / Placebo + Dapagliflozin / Placebo

    Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)

    Drug: Saxagliptin · Drug: Dapagliflozin · Drug: Placebo matching with Saxagliptin · Drug: Placebo matching with Dapagliflozin

  • Experimental
    A2: Sitagliptin / placebo

    Sitagliptin 100 mg and matching placebo 0 mg (once daily)

    Drug: Sitagliptin · Drug: Placebo matching with Sitagliptin

Interventions

  • administered orally once daily

  • administered orally once daily

  • administered orally once daily

  • DrugPlacebo matching with Saxagliptin

    administered orally once daily

  • DrugPlacebo matching with Dapagliflozin

    administered orally once daily

  • DrugPlacebo matching with Sitagliptin

    administered orally once daily

06

What researchers measure

Primary outcomes

  1. Mean Change in HbA1c

    Time frame: Baseline (randomization) to Week 26

Secondary outcomes

  1. Percent of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%

    Time frame: week 26

  2. Mean Change in Total Body Weight

    Time frame: Baseline (randomization) to Week 26

  3. Mean Change in Fasting Plasma Glucose (FPG)

    Time frame: Baseline (randomization) to Week 26

07

Results

Posted Jun 1, 2018

Participant flow

461 Patients were Randomized into the study, 411 patients completed the 26 weeks part. Out of them 402 patients continued into the additional 26 week part. Out of them 378 patients completed the 52 weeks period (26+26 weeks).

26 Week (Short Term)
Participant flow — 26 Week (Short Term)
MilestoneSAXA + DAPA + METSITA + MET
Started232229
Completed213198
Not completed1931
Withdrew: Adverse event19
Withdrew: Discontinuation by the subject22
Withdrew: Withrawal of the consent by the subject710
Withdrew: Lost to follow-up31
Withdrew: Subject no longer meets study criteria58
Withdrew: Other11
52 Week (Long Term)
Participant flow — 52 Week (Long Term)
MilestoneSAXA + DAPA + METSITA + MET
Started209193
Completed198180
Not completed1113
Withdrew: Adverse event31
Withdrew: Subject no longer meets study criteria01
Withdrew: Withrawal of the consent by the subject46
Withdrew: Lost to follow-up22
Withdrew: Non-compliance23

Outcome measures

PrimaryMean Change in HbA1c
Time frame:
Baseline (randomization) to Week 26
Reported as:
Least squares mean · percentage (%)
Mean Change in HbA1c
percentage (%)Saxagliptin + Dapagliflozin + Metformin GroupSITA + MET
Mean Change in HbA1c-1.41 ± 0.0696-1.07 ± 0.0719
Statistical analysis
  • Saxagliptin + Dapagliflozin + Metformin Group vs SITA + MET · Mixed Models Analysis · p = 0.0008 · Mean difference (final values): -0.34
SecondaryPercent of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%
Time frame:
week 26
Reported as:
Number · Percentage of subjects
Percent of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%
Percentage of subjectsSaxagliptin + Dapagliflozin + Metformin GroupSITA + MET
Percent of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%37.3 ± 3.15025.1 ± 2.871
Statistical analysis
  • Saxagliptin + Dapagliflozin + Metformin Group vs SITA + MET · Regression, Logistic · p = 0.0034 · Risk difference (rd): 12.2the analysis was by Zhang et.al. method with adjustment for baseline A1c.The measure of interest is NOT odds ratio but Risk Difference.
SecondaryMean Change in Total Body Weight
Time frame:
Baseline (randomization) to Week 26
Reported as:
Mean · kg
Mean Change in Total Body Weight
kgSaxagliptin + Dapagliflozin + Metformin GroupSITA + MET
Mean Change in Total Body Weight-1.86 ± 0.2010-0.51 ± 0.2078
Statistical analysis
  • Saxagliptin + Dapagliflozin + Metformin Group vs SITA + MET · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): -1.35
SecondaryMean Change in Fasting Plasma Glucose (FPG)
Time frame:
Baseline (randomization) to Week 26
Reported as:
Mean · mg/dl
Mean Change in Fasting Plasma Glucose (FPG)
mg/dlSaxagliptin + Dapagliflozin + Metformin GroupSITA + MET
Mean Change in Fasting Plasma Glucose (FPG)-31.9 ± 2.538-11.0 ± 2.668
Statistical analysis
  • Saxagliptin + Dapagliflozin + Metformin Group vs SITA + MET · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): -20.9

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SAXA + DAPA + MET0/232 (0%)9/232 (3.9%)112/232 (48.3%)
Sita + Met0/229 (0%)13/229 (5.7%)123/229 (53.7%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventSAXA + DAPA + METSita + Met
ENDOMETRIOSISReproductive system and breast disorders0/2322/229
PNEUMONIAInfections and infestations0/2322/229
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/2322/229
ATRIAL FIBRILLATIONCardiac disorders0/2321/229
CARDIAC FAILURE CHRONICCardiac disorders0/2321/229
CARDIAC FAILURE CONGESTIVECardiac disorders0/2321/229
CONGESTIVE CARDIOMYOPATHYCardiac disorders0/2321/229
MITRAL VALVE PROLAPSECardiac disorders0/2321/229
TACHYCARDIACardiac disorders0/2321/229
ABDOMINAL PAINGastrointestinal disorders0/2321/229
Most frequent other events
Showing 10 of 21
Most frequent other events
EventSAXA + DAPA + METSita + Met
NASOPHARYNGITISInfections and infestations18/23212/229
HEADACHENervous system disorders13/23210/229
INFLUENZAInfections and infestations8/23211/229
URINARY TRACT INFECTIONRenal and urinary disorders10/2327/229
BACK PAINMusculoskeletal and connective tissue disorders5/2329/229
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations7/2328/229
HYPERTENSIONVascular disorders3/2328/229
BRONCHITISInfections and infestations8/2322/229
COUGHRespiratory, thoracic and mediastinal disorders3/2327/229
ANAEMIABlood and lymphatic system disorders1/2327/229

Baseline characteristics

Age, Continuous
Age, Continuous(years)SAXA + DAPA + METSITA + METTotal
Mean55.9 ± 8.8755.8 ± 9.5555.9 ± 9.21
Sex: Female, Male
Sex: Female, Male(Participants)SAXA + DAPA + METSITA + METTotal
Female132119251
Male100110210
Region of Enrollment
Region of Enrollment(participants)SAXA + DAPA + METSITA + METTotal
Europe7274146
North America114113227
Central America464288
08

Study locations

79 sites
  • Research Site
    Mesa, Arizona 85206, United States
  • Research Site
    Mesa, Arizona 85213, United States
  • Research Site
    Phoenix, Arizona 85020, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Huntington Beach, California 92648, United States
  • Research Site
    Huntington Park, California 90255, United States
  • Research Site
    Lomita, California 90717, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    Northridge, California 91325, United States
  • Research Site
    Norwalk, California 90650, United States
  • Research Site
    Paramount, California 90723, United States
  • Research Site
    Sacramento, California 95823, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Tustin, California 92780, United States
  • Research Site
    Golden, Colorado 80401, United States
  • Research Site
    Coral Gables, Florida 33134, United States
  • Research Site
    Kissimmee, Florida 34744, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Miami, Florida 33015, United States
  • Research Site
    Miami, Florida 33135, United States
  • Research Site
    Miami, Florida 33174, United States
  • Research Site
    Palm Harbor, Florida 34684, United States
  • Research Site
    Pembroke Pines, Florida 33026, United States
  • Research Site
    Chicago, Illinois 60634, United States
  • Research Site
    Council Bluffs, Iowa 51503, United States
  • Research Site
    Crestview Hills, Kentucky 41017, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Morehead City, North Carolina 28557, United States
  • Research Site
    Salisbury, North Carolina 28144, United States
  • Research Site
    Norman, Oklahoma 73069, United States
  • Research Site
    Columbia, South Carolina 29204, United States
  • Research Site
    Bristol, Tennessee 37620, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Houston, Texas 77081, United States
  • Research Site
    North Richland Hills, Texas 76180, United States
  • Research Site
    Pasadena, Texas 77504, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Manassas, Virginia 20110, United States
  • Research Site
    Suffolk, Virginia 23452, United States
  • Research Site
    Kenosha, Wisconsin 53142, United States
  • Research Site
    Baja, 6500, Hungary
  • Research Site
    Budapest, 1036, Hungary
  • Research Site
    Budapest, 1097, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Gyula, 5700, Hungary
  • Research Site
    Nyíregyháza, 4405, Hungary
  • Research Site
    Szekszárd, 7100, Hungary
  • Research Site
    Aguascalientes, 20230, Mexico
  • Research Site
    Chihuahua, 31217, Mexico
  • Research Site
    Cuautla, 62746, Mexico
  • Research Site
    Guadalajara, 44130, Mexico
  • Research Site
    Guadalajara, 44160, Mexico
  • Research Site
    Guadalajara, 44670, Mexico
  • Research Site
    Monterrey, 64460, Mexico
  • Research Site
    Białystok, 15-879, Poland
  • Research Site
    Gdańsk, 80-546, Poland
  • Research Site
    Kraków, 31-156, Poland
  • Research Site
    Kraków, 31-261, Poland
  • Research Site
    Opole, 45-367, Poland
  • Research Site
    Poznań, 61-655, Poland
  • Research Site
    Warszawa, 02-507, Poland
  • Research Site
    Wroclaw, 50-349, Poland
  • Research Site
    Wroclaw, 51-685, Poland
  • Research Site
    Brasov, 500269, Romania
  • Research Site
    Bucuresti, 011794, Romania
  • Research Site
    Bucuresti, 020359, Romania
  • Research Site
    Buzau, 120203, Romania
  • Research Site
    Craiova, 200349, Romania
  • Research Site
    Galati, 800098, Romania
  • Research Site
    Oradea, 410169, Romania
  • Research Site
    Satu-Mare, 440055, Romania
  • Research Site
    Timisoara, 300736, Romania
  • Research Site
    Boksburg North, 1460, South Africa
  • Research Site
    Cape Town, 7700, South Africa
  • Research Site
    Durban, 4091, South Africa
  • Research Site
    Johannesburg, 1818, South Africa
  • Research Site
    Lenasia, 1829, South Africa
  • Research Site
    Moloto, 1022, South Africa
  • Research Site
    Soweto, 2013, South Africa
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Sep 2016, 24 months.

Results were first posted in Jun 2018, 1 year 8 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 24 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2014
First posted
Nov 6, 2014
StartActual
Sep 9, 2014
Primary completionActual
Sep 20, 2016
CompletionActual
Sep 20, 2016
Results first posted
Jun 1, 2018
Last update
Jun 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02284893
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 6, 2014
Start date
Sep 9, 2014
Primary completion
Sep 20, 2016
Completion
Sep 20, 2016
Results posted
Jun 1, 2018
Last update
Jun 1, 2018

Study contacts

Astra Zeneca
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Dapagliflozin · Sitagliptin

Start the discussion